分次照射诱导肿瘤细胞产生短暂放射抵抗
该体外研究用临床分次方案(2 Gy/次、每日、每周5天、共6周)照射结肠癌与高级别星形细胞瘤细胞系,发现所有细胞系在2–3周内出现可逆的放射抵抗,表现为克隆存活进入稳态;恢复后放射敏感性与未照射细胞相似,且将短暂放射抵抗以(α/β)-(d+1)纳入LQ模型可完美拟合实验数据。
要点
- 临床分次方案照射2–3周后肿瘤细胞系出现可逆的放射抵抗。
- 抵抗期以克隆存活进入稳态为特征,U-251MG伴衰老与干性增加。
- 将(α/β)-(d+1)纳入LQ模型可拟合分次照射期间的存活数据。
核心结论
- 按临床放疗方案进行体外分次照射可诱导肿瘤细胞产生可逆的放射抵抗,该适应性反应可作为分次剂量与细胞系α/β比值的函数纳入LQ模型。
研究设计与样本
- 体外研究,采用结肠癌细胞系HT29、HCT116、COLO320、SW480、RKO与高级别星形细胞瘤细胞系D384、U-251MG,按每日2 Gy、每周5天、共6周进行分次照射,全程测定克隆存活。
- 比较照射与未照射细胞的放射敏感性,并观察不同分次剂量对放射抵抗发生的影响。
主要发现
- 所有细胞系在分次放疗2–3周内出现放射抵抗,特征为克隆存活进入稳态阶段。
- U-251MG细胞出现放射抵抗时伴随细胞衰老与干性增加。
- 结束6周处理并恢复后,分次照射细胞与未照射细胞的放射敏感性相似。
- 将短暂放射抵抗描述为(α/β)-(d+1)并纳入经典LQ模型,与分次放疗期间观察到的实验数据完美拟合,并在应用不同分次剂量时得到确认。
关键数值与推荐
- 分次照射方案为每日2 Gy、每周5天、共6周。
- 放射抵抗在分次放疗2–3周内出现,表现为克隆存活稳态。
- 将短暂放射抵抗以(α/β)-(d+1)纳入LQ模型可完美拟合实验数据。
临床怎么用
- 解读分次放疗期间的存活数据时需考虑可逆的适应性放射抵抗,而非仅按初始放射敏感性推断。
- LQ模型中加入(α/β)-(d+1)项可能有助于描述分次照射过程中的动态反应,但尚需进一步验证。
局限性
- 研究为体外细胞系实验,放射抵抗的机制与临床相关性仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Effective combination treatments with fractionated radiotherapy rely on a proper understanding of the dynamic responses that occur during treatment. We explored the effect of clinical fractionated radiotherapy on the development and timing of radioresistance in tumor cells. METHODS AND MATERIALS: Different colon (HT29/HCT116/COLO320/SW480/RKO) and high-grade astrocytoma (D384/U-251MG) cancer cell lines were treated for 6 weeks with daily fractions of 2 Gy, 5 days per week. Clonogenic survival was determined throughout the treatment period. In addition, the radiosensitivity of irradiated and non-irradiated was compared. Finally, the effect of different dose fractions on the development of radioresistance was determined. RESULTS: All cell lines developed radioresistance within 2-3 weeks during fractionated radiotherapy. This was characterized by the occurrence of a steady state phase of clonogenic survival. In U-251MG cells this was accompanied by increased cell senescence and stemness. After recovering from six weeks of treatment, the radiosensitivity of fractionally irradiated and non-irradiated cells was similar. Including transient radioresistance, described as (α/β)-(d+1), as a factor in the classic LQ model resulted in a perfect fit with the experimental data observed during fractionated radiotherapy. This was confirmed when different dose fractions were applied. CONCLUSIONS: Fractionated irradiation of cancer cells in vitro following clinical radiation schedules induces a reversible radioresistance response. This adaptive response can be included in the LQ model as a function of the dose fraction and the alpha/beta-ratio of a given cell line. These findings warrant further investigation of the mechanisms and clinical relevance of adaptive radioresistance.
引用
- van den Berg J, Castricum KCM, Meel MH, et al. Development of transient radioresistance during fractionated irradiation in vitro. Radiother Oncol. 2020. PMID: 32344261. doi:10.1016/j.radonc.2020.04.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。